as on November 1, 2025 at 1:29 am IST
Day's Low
Day's High

2.55%
Downside
3.04%
Upside

52 Week's Low
52 Week's High

77.43%
Downside
2.19%
Upside

Check Arrowhead Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$5.8B
EPS (TTM)
-0.2791
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.10%
PE Ratio (TTM)
-5.56
Industry PE ratio
9.621739130434783
PEG Ratio
-1.32
EBITDA
-85.4M
Revenue (TTM)
573.0M
Profit Margin
-25.90%
Return On Equity TTM
-37.11%
Track how Arrowhead Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Arrowhead Pharmaceuticals, Inc. in the last 5 years
Lowest (-72.52x)
March 31, 2021
Today (-5.56x)
October 31, 2025
Industry (9.62x)
October 31, 2025
Highest (-3.99x)
December 31, 2024
Today’s Price to Earnings Ratio: -5.56x
Compare market cap, revenue, PE, and other key metrics of Arrowhead Pharmaceuticals, Inc. with its industry peers.
| Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | 
|---|---|---|---|---|---|
| BUY | $5.8B | -26.16% | -5.56 | -25.90% | |
| BUY | $41.1B | 489.62% | -16.34 | -259.82% | |
| BUY | $63.1B | 265.59% | -505.15 | -12.96% | |
| BUY | $107.0B | 101.52% | 29.67 | 31.86% | |
| BUY | $68.6B | 20.33% | 15.65 | 32.13% | 
The Arrowhead Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Arrowhead Pharmaceuticals, Inc. investment value today
Current value as on today
₹2,26,130
Returns
₹1,26,130
(+126.13%)
Returns from Arrowhead Pharmaceuticals, Inc. Stock
₹1,20,489 (+120.49%)
Dollar Returns*
₹5,642 (+5.64%)
Based on 20 analysts
75.00%
Buy
25.00%
Hold
0.00%
Sell
Based on 20 analysts, 75% of analysts recommend a 'BUY' rating for Arrowhead Pharmaceuticals, Inc.. Average target price of $47.5
Get share price movements and forecasts by analysts on Arrowhead Pharmaceuticals, Inc..
What analysts predicted
10.74%UPSIDE
Target Price
$47.5
Current Price
$42.4
Analyzed by
20 Analysts
Target
$47.50
Arrowhead Pharmaceuticals, Inc. target price $47.5, a slight upside of 10.74% compared to current price of $42.4. According to 20 analysts rating.
Search interest for Arrowhead Pharmaceuticals, Inc. Stock has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD

Today's Timeline - 01 August
Fri, 04:00 PM
-Arrowhead's subsidiary Visirna sells rights to plozasiran in Greater China to Sanofi for $130 million upfront.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
 POSITIVE IMPACT
POSITIVE IMPACTPrice Rise

In the last 7 days, ARWR stock has moved up by 11.3%
 NO EFFECT
NO EFFECTAgainst Peers

In the last 1 year, Insmed Incorporated has given 188.7% return, outperforming this stock by 68.7%
 NO EFFECT
NO EFFECTAgainst Peers

In the last 3 years, Insmed Incorporated has given 1021.4% return, outperforming this stock by 999.9%
 NEGATIVE IMPACT
NEGATIVE IMPACTRevenue Fall

Revenue is down for the last 2 quarters, 542.70M → 27.76M (in $), with an average decrease of 94.9% per quarter
 NEGATIVE IMPACT
NEGATIVE IMPACTProfit Down

Netprofit is down for the last 2 quarters, 370.44M → -175.24M (in $), with an average decrease of 147.3% per quarter
| Organisation | Arrowhead Pharmaceuticals, Inc. | 
| Headquarters | 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 | 
| Industry | Health Technology | 
| CEO | Dr. Christopher R. Anzalone Ph.D. | 
| E-voting on shares | Click here to vote | 
| Name | Title | 
|---|---|
| Aaron Tan | Head of Tax | 
| Mr. Daniel J. Apel | Chief Financial Officer | 
| Mr. Patrick O'Brien J.D., PharmD | COO, General Counsel & Secretary | 
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of R&D | 
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | 
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP | 
| Mr. Howard Lovy | Director of Communications | 
| Dr. Bruce D. Given M.D. | Chief Medical Scientist | 
| Dr. Mark Seefeld | Head of Toxicology & VP | 
| Dr. Christopher R. Anzalone Ph.D. | Chairman, CEO & President | 
Arrowhead Pharmaceuticals, Inc. share price today is $42.4 as on at the close of the market. Arrowhead Pharmaceuticals, Inc. share today touched a day high of $43.69 and a low of $41.32.
Arrowhead Pharmaceuticals, Inc. share touched a 52 week high of $43.33 on and a 52 week low of $9.57 on . Arrowhead Pharmaceuticals, Inc. stock price today i.e. is closed at $42.4,which is 2.15% down from its 52 week high and 343.05% up from its 52 week low.
Arrowhead Pharmaceuticals, Inc. market capitalisation is $0.01T as on .
Indian investors can start investing in Arrowhead Pharmaceuticals, Inc. (ARWR) shares with as little as ₹88.665 or $1 (as of ) using the INDmoney app. 
      
      For example: If you want to invest $10 or ₹886.65 in Arrowhead Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ). 
        Based on Arrowhead Pharmaceuticals, Inc. share’s latest price of $42.4 as on November 1, 2025 at 1:29 am IST, you will get 0.2358 shares of Arrowhead Pharmaceuticals, Inc.. Learn more about
          
            fractional shares .
        
Arrowhead Pharmaceuticals, Inc. stock has given -26.16% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
        
 Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?